PHIA Koninklijke Philips N.V.

Philips expands peripheral vascular disease portfolio with the QuickClear mechanical thrombectomy system for blood clot removal

Philips expands peripheral vascular disease portfolio with the QuickClear mechanical thrombectomy system for blood clot removal



September 24, 2020

  • Powerfully simple thrombectomy solution provides physicians with an all-in-one, single-use aspiration catheter and pump system
  • Intuitive design eliminates the need for capital equipment, with easy setup supporting faster procedures times
  • Significantly smaller footprint provides the same or greater aspiration power as currently-available thrombectomy devices [1]      

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the innovative QuickClear mechanical thrombectomy system. The compact, single-use system provides an all-in-one aspiration pump and catheter for the removal of blood clots from the vessels of the peripheral arterial and venous systems [2]. The system’s innovative all-in-one design is simple to use while eliminating the need for capital equipment or costly accessories, with easy setup supporting faster procedures times. The Philips QuickClear Mechanical Thrombectomy System has received U.S. FDA 510(k) clearance and is available for sale in the U.S.

“This novel thrombectomy system is the latest addition to Philips’ market-leading portfolio for the diagnosis and treatment of peripheral vascular diseases,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “Its intuitive design simplifies the entire thrombectomy procedure workflow. By taking away the high initial capital expenditure costs associated with traditional mechanical thrombectomy systems, QuickClear can help bring cost-effective solutions to both the hospital and outpatient care settings.”

Simple, optimized performance

QuickClear simplifies the entire thrombectomy procedure workflow. The small footprint of the sterile device allows it to be placed easily and conveniently on the table next to the patient. With the touch of a button, the system is up and running at maximum aspiration power within seconds. The consistency of the aspiration power during the procedure provides physicians more control and supports faster procedure times. The system’s range of catheters includes a large 10F aspiration catheter, providing 59% more aspiration volume than 8F aspiration catheters [1].

“QuickClear is a simple and easy to use mechanical thrombectomy system,” said Bryan Fisher, MD, Chief of Vascular Surgery, Tristar Centennial Medical Center, Nashville, U.S. “The system is significantly smaller than other systems without compromising aspiration power. The convenience of the device really shines through with its single use and lack of capital equipment. I am excited about the potential of this device and the impact it will have on my practice and the patients I treat.”

Philips’ peripheral vascular portfolio already includes advanced interventional imaging systems for precision guidance; intravascular ultrasound (IVUS) catheters to assess the location of the disease and lesion morphology and guide and confirm the treatment; peripheral atherectomy devices to remove blockages; and peripheral therapy devices, such as Philips’ Stellarex drug-coated balloon, to treat lesions. Philips recently further extended this portfolio with the , maker of the Tack Endovascular System, a first-of-its-kind, minimal-metal, dissection repair device that provides precision treatment of peripheral arterial dissections following balloon angioplasty in above-the-knee (ATK) and below-the-knee (BTK) therapeutic interventions.

New Cardiovascular Horizons digital symposium

Today, September 24th at 19:00 ET Philips will host a symposium entitled ‘QuickClear Mechanical Thrombectomy System: A Powerfully Simple and Cost-Effective Solution’ as part of the digital education series. To register, visit .

The Philips QuickClear Mechanical Thrombectomy System is U.S. FDA 510(k) cleared and available for sale in the U.S., with future expansion of availability to other geographies planned.

[1] Testing performed in-house. Data on file.

[2] The Philips QuickClear mechanical thrombectomy system is indicated for the removal of soft, fresh emboli and thrombi from the vessels of the peripheral arterial and venous systems.

For further information, please contact:

Mark Groves

Philips Global Press Office

Tel:

Email:



Twitter:

Fabienne van der Feer

Philips Image Guided Therapy

Tel:

Email:



Twitter:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments

EN
24/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new...

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member April 2, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the of the Medical Device Innovation Consortium (). Founded in 2012, MDIC is a unique public-private partnership that brings stakeholders across the medical device spectrum together with the US Food and Drug Administration () and other agency partners to help ensure patient access to medical device inn...

 PRESS RELEASE

FDA clears Philips AI solution that provides real-time guidance during...

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA...

 PRESS RELEASE

Philips launches IntraSight Plus to simplify coronary interventions an...

Philips launches IntraSight Plus to simplify coronary interventions and advance precision care March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient careWith FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips remains No. 1 in Medtech at European Patent Office and the lar...

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.Philips’ platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges.Philips’ innovation improved the lives of 2 billion people in 2025, with the goal of improving 2.5 billion lives per year by 2030, including 400 million people in medically unde...

 PRESS RELEASE

Philips convenes the Annual General Meeting of Shareholders 2026

Philips convenes the Annual General Meeting of Shareholders 2026 March 23, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch